Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This source reports that an international panel of dermatologists has provided a consensus statement to guide clinicians on the off-label use of low-dose oral minoxidil for treating hair loss.

In this study of patients with androgenetic alopecia taking off-label low-dose oral minoxidil, adverse events like dizziness/lightheadedness, hypertrichosis, and extremity edema were observed in 14.9% of patients, with females experiencing more adverse events; higher doses increased dizziness risk, leading researchers to recommend cautious dosing approaches.

This study examined the FDA Adverse Event Reporting System database and found significant associations between low-dose oral minoxidil use and adverse events like pericardial effusion, highlighting the need for caution and recommending the use of the lowest effective dose until more safety data are available.

Both treatment combinations improved hair growth similarly and were safe.

This study addresses the scarcity of information on the effectiveness and safety of low-dose oral minoxidil for treating COVID-19-associated telogen effluvium, a type of hair loss observed in some patients after COVID-19 infection, but does not report specific results.

In this study, low-dose oral minoxidil was found to be an effective and safe treatment for androgenetic alopecia, showing comparable outcomes in patients with AGA alone and those with AGA unmasked by telogen effluvium.

In this study, researchers found that low-dose oral minoxidil for androgenetic alopecia in men generally showed a good safety profile, with hypertrichosis being the most frequent side effect, while systemic side effects like dizziness and hypotension were less common and no life-threatening effects were observed.

Low-dose minoxidil helps hair grow longer and thicker in people with short anagen syndrome.

In this study, a survey of 84 Saudi Arabian dermatologists found increasing use of low-dose oral Minoxidil for hair loss management, though the limited sample size and English questionnaire may affect how well the findings represent the entire dermatologist population in the country.

This source suggests that oral minoxidil could be a safe and effective treatment option for both female and male androgenetic alopecia, although it is currently used off-label.

This article discusses the use of low-dose oral minoxidil as an off-label treatment for androgenetic alopecia but reports no new clinical results.

This review evaluates the clinical experience of using low-dose oral minoxidil for treating alopecia and highlights the ongoing concerns about its potential side effects without reporting new clinical results.

Low-dose oral minoxidil is safe for treating hair loss, especially in women, with side effects stopping after use ends.

This study evaluated low dose oral minoxidil as a treatment for female pattern hair loss but reports no new clinical results.

This study reported that low dose oral minoxidil may help treat persistent chemotherapy-induced alopecia, based on a retrospective case series involving 15 patients across multiple centers.

This study illustrates that low-dose oral minoxidil shows clinically notable hair regrowth, particularly at the crown in male patients, with differing efficacy from bitemporal sites; images document regrowth in a male and a female patient.

This publication discusses the use of low-dose oral minoxidil for treating traction alopecia but reports no new clinical outcomes; further research on its efficacy and safety is needed.

This review highlights emerging evidence that low-dose oral minoxidil could be used off-label to treat androgenetic alopecia, offering insights into its potential mechanisms and clinical applications beyond its current role in treating hypertension.

This study found that both oral minoxidil and finasteride altered prostate tissue in mice, with more severe changes seen in finasteride-treated groups, suggesting greater implications for male reproductive health compared to minoxidil.

This study found that the orally disintegrating tablet and standard tablet formulations of finasteride met bioequivalence criteria in fasting healthy adult male Han Chinese volunteers, although there was a significant difference in time to maximum concentration.

This study reviewed the literature on low-dose oral minoxidil as a primary treatment for various hair loss disorders, concluding that it is a successful and well-tolerated alternative to topical minoxidil for patients with poor adherence to other therapies.

This case series reports the experience of using oral minoxidil at 1.25 mg/day in 32 patients with male androgenetic alopecia, noting both therapeutic effects and potential adverse reactions.

This study reports serious adverse effects resulting from compounding errors when using low-dose oral minoxidil to treat alopecia.

This review discusses the emerging evidence for low-dose oral minoxidil in treating various types of alopecia, without providing new clinical results.

This abstract reviews the use of low dose oral minoxidil as a monotherapy for hair loss and reports no new clinical data.

This case report identified a possible adverse effect of low-dose oral minoxidil for female pattern hair loss, as a 74-year-old woman developed significant dry mouth that resolved after stopping the medication and recurred upon rechallenge, suggesting a causal link.

This prospective study reported that 5 mg daily oral low-dose minoxidil over 24 weeks led to a high prevalence of hypertrichosis in 93% of male androgenetic alopecia patients, particularly affecting younger individuals, but generally had minimal impact on patients’ quality of life.

This study concluded that while both 5% topical and 1 mg oral minoxidil significantly improved hair diameter in androgenetic alopecia patients, there was no significant difference in overall effectiveness or patient satisfaction between the treatments.